Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Follow-Up Questions
Who is the CEO of Unicycive Therapeutics Inc?
Dr. Shalabh Gupta is the Chairman of the Board of Unicycive Therapeutics Inc, joining the firm since 2016.
What is the price performance of UNCY stock?
The current price of UNCY is $4.43, it has decreased 0.11% in the last trading day.
What are the primary business themes or industries for Unicycive Therapeutics Inc?
Unicycive Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Unicycive Therapeutics Inc market cap?
Unicycive Therapeutics Inc's current market cap is $78.3M
Is Unicycive Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Unicycive Therapeutics Inc, including 3 strong buy, 10 buy, 1 hold, 0 sell, and 3 strong sell
